Company Description

Sisu Pharma is exploiting the power of the cellular stress response, directly targeting Heat Shock Factor 1 (HSF1) - the key regulator of the heat shock response. Through their innovative HSF1 targeting platform, HI-LiTe, they are advancing selective HSF1 degraders for oncology and activators for neurodegenerative diseases.